Personalized Needs in Clostridium Difficile Infections (SPECIFY)
Scoring Personalized Needs in Clostridium Difficile Infections for Fidaxomixin Therapy
研究概览
详细说明
Medical world is nowadays witnessing a sudden increase of the incidence of infections by Clostridium difficile (DCI). This is due in part to the prolongation of survival of patients with major comorbidities like solid tumor malignancies and lymphomas but also to the widespread intake of proton pump inhibitors and of wide-spectrum antimicrobials. It is highly probable that isolates of C.define causing this pandemic are genetically different than isolates of the same species predominating 20 years ago. This hypothesis is developed based on data of the epidemiology of CDI: in old times administration of clindamycin and ampicillin were the main drivers of CDI; recent studies report fluoroquinolones, 2nd and 3rd generation cephalosporins and even vancomycin (i.e. a drug of choice for CDI) to be linked with the development of CDI.
One major hurdle in management of CDI is relapse; the risk of relapse is reported as 15-20% after the first episode; however it is geometrically increased to even 60-80% after the second episode. As a consequence, management of CDI becomes a major health problem.
Fidaxomicin is a novel compound active against species of C.dificille. Results of two recent double-blind, randomized, large scale clinical studies have shown that oral treatment for 10 days with fidaxomicin 200mg bid was non-inferior to oral treatment with vancomycin 125mg q6h. However, the risk of relapse after treatment with vancomycin was close to 25% and with fidaxomicin close to 15%. This difference was statistically significant in both trials outscoring the superiority of fidaxomicin over vancomycin for the management of CDI. Moreover, meta-analysis has shown a significant reduction in mortality by fidaxomicin.
Despite proven superiority, prescription of fidaxomicin is limited to few cases mostly due to high cost. In many countries prescription is restricted to cases of relapsing CDI. Clinical feeling coming both from post-marketing experience as well as from published evidence supports the use of fidaxomicin for cases with risk of death and overt risk of relapse. However, molecular analysis of the C.difficile pathogen cannot be used as a tool for the prediction of relapse since in relapse cases pathogens carry less than 2 single nucleotide variants of the initial isolate. SPECIFY is aiming to develop a score using both clinical and genetic and biomarker data that can efficiently discriminate patients at risk of severe CDI and at risk of relapse of CDI. This score can become in future a tool to discriminate patients at need for treatment with fidaxomicin instead of traditional treatment with metronidazole/vancomycin.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Athens、希腊、10676
- 5th Department of Internal Medicine, Evangelismos Athens General Hospital
-
Athens、希腊、11527
- 1st Department of Internal Medicine, "G.Gennimatas" General hospital
-
Athens、希腊、11527
- 1st Department of Internal Medicine, Laikon General Hospital
-
Athens、希腊、11527
- 3rd Department of Internal Medicine, Sotiria General Hospital
-
Athens、希腊、12462
- 4th Department of Internal Medicine, Attikon University Hospital
-
Athens、希腊、15126
- 2nd Department of Internal Medicine, Sismanogleion General Hospital
-
Magoula、希腊、10918
- 1st Department of Internal Medicine, Thriassio General Hospital
-
Magoula、希腊、10918
- 2nd Department of Internal Medicine, Thriasio General Hospital
-
Maroúsi、希腊、15123
- 2nd Department of Oncology, Mitera Hospital
-
Piraeus、希腊
- Infections Unit Tzaneion General Hospital
-
Pátra、希腊、36504
- Department of Internal Medicine, Patras University Hospital
-
Thessaloniki、希腊、54248
- 1st Department of Internal Medicine, AHEPA University Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Age equal to or more than 18 years
- Both genders
- Diarrhea defined as at least 3 episodes of unformed stools in the last 24 hours according to the Bristol stool chart
- Presence of C.difficile in stool. This is defined as any stool sample positive for the presence of glutamate dehydrogenase (GDH) and for the presence of toxin A and/or B.
Exclusion Criteria:
1. No exclusion criteria exist
学习计划
研究是如何设计的?
设计细节
- 观测模型:仅案例
- 时间观点:预期
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Clostridium difficile infection
Patients with Clostridium difficile-associated diarrhea for development of biomarkers
|
Blood sampling
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Definition of prognostic biomarker
大体时间:12 months
|
Patients with positive score and unfavorable outcome.
Unfavorable outcome is defined as at least one of the following: a) number of patients with severe infection at disease onset; b) number of patients who progress into severe infection; c) number of patients with disease recurrence; and d) number of patients who die
|
12 months
|
合作者和调查者
调查人员
- 首席研究员:Athanasios Skoutelis, MD、Evangelismos Athens General Hospital
- 学习椅:Evangelos J Giamarellos-Bourboulis, MD, PhD、Attikon Hospital
- 首席研究员:George Chrysos, MD, PhD、Tzaneion Piraeus General Hospital
- 首席研究员:Styliani Symbardi, MD, PhD、Thriassio Elefsis General Hospital
- 首席研究员:Zoi Alexiou, MD, PhD、Thriassio Elefsis General Hospital
- 首席研究员:Kostantinos Syrigos, MD, PhD、Sotiria General Hospital
- 首席研究员:George Daikos, MD, PhD、Laikon Athens General Hospital
- 首席研究员:Panagiotis Gargalianos, MD, PhD、G.Gennimatas Athens General Hospital
- 首席研究员:Malvina Lada, MD, PhD、Sismanogleion General Hospital
- 首席研究员:Charalambos Gogos, MD, PhD、University Hospital of Patras
- 首席研究员:Ilias Athanasiadis, MD, PhD、Mitera General Hospital
- 首席研究员:Symeon Metallidis, MD, PhD、AHEPA Thessaloniki University Hospital
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.